opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanóma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.
novo dual tõgyfertõtlenítõ
agroszász kft. -
blincyto
amgen europe b.v. - blinatumomab - prekurzorsejt limfoblasztikus leukémia-limfóma - daganatellenes szerek - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
esmeron 10 mg/ml oldatos injekció
msd pharma hungary kft. - rocuronium-bromid -
methotrexat-lachema 5 mg/2 ml injekció
pliva-lachema a.s. - metotrexát -
methotrexat-lachema 50 mg/5 ml injekció
pliva-lachema a.s. - metotrexát -
methotrexat-lachema 1000 mg/20 ml injekció
pliva-lachema a.s. - metotrexát -
venomenhal darázs por és oldószer oldatos injekcióhoz
hal allergy bv - allergén kivonat -